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Purpose: The precise molecular mechanisms culminating in
coronary artery disease (CAD) are not well understood, despite
a wealth of knowledge on predisposing risk factors and
pathomechanisms. CAD and myocardial infarction (MI) are
complex genetic diseases; neither the environment alone, nor
a single gene, cause disease, rather, a mix of environmental
and genetic factors lead to atherosclerosis of the coronary
arteries. Materials and Methods: In the present study, our aim
was to investigate the roles of prothrombin G20210A mutation
and Factor VLeiden mutation in atherosclerotic coronary artery
disease. 287 subjects (106 control subjects, who were angio-
graphically normal, and 181 angiographically documented
coronary atherosclerotic patients who exhibited coronary
artery narrowing to a degree of 50%) were included in this
study. The mutations were assessed with LightCycler Real-
Time PCR mutation detection kits (Roche Diagnostics, GmbH,
Germany). Results: 6.6% of control subjects, and 6.1% of
patients with (50% coronary artery narrowing were deter-
mined to have the Factor VLeiden heterozygote mutation.
6.6% of control subjects had the Prothrombin G20210A
heterozygote mutation, while 7.7% of patients with (50%
coronary artery narrowing had this mutation. The OR for
Factor VLeiden was 1.52 (CI: 0.240 - 9.602) and for
Prothrombin G20210A mutation, the OR was 1.415 (CI: 0.287
- 6.962). Conclusion: Although both the heterozygote Factor
VLeiden and Prothrombin gene mutations were more frequent
in patients with CAD than in control subjects, there was no
statistical relationship found to exist between coronary artery
disease and the Factor VLeiden and Prothrombin G20210A
mutations.
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INTRODUCTION
Cardiovascular disease is the result of an inter-
action between environmental influences and
genetic predisposition. In addition to the well-
accepted traditional risk factors, there is increasing
evidence suggesting that coagulation may be in-
volved in the pathogenesis of atherosclerosis, and
also in the clinical progression to plaque rupture
and localized occlusive thrombus formation.
1
The association between environmental factors
and myocardial infarction has been thoroughly
investigated, but the role of genetic markers is still
poorly defined.
2 Over the past few years, studies
have focused on the role of haemostatic markers,
which reflect inherited or acquired propensities
for thrombosis and/or the extent of subclinical
atherosclerosis, and several genetic mutations
affecting coagulation proteins, which have been
suggested as prothrombotic risk factors.
3,4
Several studies have recently examined the rela-
tionship between myocardial infarction and pro-
thrombotic genetic markers, such as the 4G/5G
polymorphism of the PAI-1 gene promoter, PIA1/
PIA2 polymorphism of the platelet glycoprotein
IIIa gene, C3550T polymorphism of the platelet
glycoprotein Ib gene, C677T polymorphism of the
methylenetetrahydrofolate reductase gene, and
the G10976A polymorphism (Arg353Gln) of the
factor VII gene. However, conclusions regarding
genotype and allele frequencies have been incon-
sistent.
5-7 Two other polymorphisms, the G1691A
mutation in the Factor V gene,
8 and the G20210A
mutation in the prothrombin gene,
9 are definitely
associated with an increased risk of venous
thrombosis, but whether they are associated with
a risk of arterial thrombosis remains controversial.
Factor VLeiden and Prothrombin G20210A Gene
Polymorphisms in Patients with Coronary Artery Disease
Bahadır Ercan,
1 Lülüfer Tamer,
1 Nehir Sucu,
2 Hasan Pekdemir,
3 Ahmet Çamsarı,
3 and Uğur Atik
1
Departments of
1Biochemistry,
2Cardiovascular Surgery and
3Cardiology, Mersin University, Medical Faculty, Mersin, Turkey.
Received December 31, 2003
Accepted May 29, 2004
Reprint address: requests to Dr. Lülüfer Tamer, Mersin
Üniversitesi TIP Fakultesi, Araştırma ve U ygulama Hastanesi,
Biyokimya AD, 33070 Mersin, Turkiye. Tel: 90-324-3374300, Fax:
90-324-3374305, E-mail: lutamer@yahoo.comBahadır Ercan, et al.
Yonsei Med J Vol. 49, No. 2, 2008
The Prothrombin G20210A mutation was
associated with a higher prothrombin clotting
activity and a 2- to 7- fold increase in risk of
venous thrombosis.
9 Other groups reported
similar findings.
10-12 The role of the prothrombin
gene G20210A variant in CAD has not yet been
established. Several investigators, however, have
reported a significant increase in the prevalence of
the prothrombin gene G20210A variant in patients
with CAD (1.8% to 12.5%), compared with new-
borns or age-matched controls,
13-15 and a 4-fold
increase in risk of myocardial infarction in young
women with this variant.
16 Others found no in-
creased prevalence of the prothrombin gene
G20210A variant in patients with CAD, compared
with age and sex-matched controls.
17-19
The relationship between the Factor VLeiden
mutation and CAD is also still controversial.
Several investigators have uncovered a significant
association between Factor VLeiden and coronary
artery disease,
20-22 or have found an increased
prevalence of Active Protein C (APC) resistance in
stroke patients,
23 whereas other groups reported
no association between APC resistance or Factor
VLeiden and coronary artery disease
23-25 or ischemic
stroke
15,18,24 respectively.
In the present study, we investigated a possible
association between Factor V, Prothrombin G20210A
mutation and subjects with angiographically
documented CAD.
MATERIALS AND METHODS
Subjects
287 subjects (106 controls, who were angiogra-
phically normal, and 181 angiographically docu-
mented coronary atherosclerotic patients who had
(50% coronary artery narrowing) were included in
this study. Of one hundred and eighty-one patients,
114 males (58.2 ± 10) and 67 females (58.5 ± 10)
underwent percutaneous transluminal coronary
angioplasty (PTCA) or coronary bypass grafting
(CABG) surgery, with diagnoses of 50% stenosis
in at least one of the major coronary arteries
constituting the study group. The other 52 male
(57.6 ± 10) and 54 female (57.1 ± 10) subjects,
whose coronary angiographies turned out to be
normal, formed the control group. The patients
who had triglyceride levels of more than 400 mg/
dL were excluded because Low Density Lipoprotein
(LDL) content is calculated from primary
measurements using the empirical equation. The
demographic data of patients and controls are
given in Table 1. The patients and controls were
from the same geographic region and of the same
ethnic origin. Also, cases and controls were
unrelated. This study was carried out according to
the principles of the Declaration of Helsinki, and
was approved by the Mersin University School of
Medicine, and an investigational review board. In-
formed consent was obtained from all partici-
pating patients.
DNA isolation
Venous blood was collected by venipuncture, in
sterile siliconized EDTA 2-mL Vacutainer tubes,
and stored at + 4 until time of analysis. Genomic
DNA was extracted from whole blood using High
Pure PCR Template Preparation kits (Roche Diag-
nostics, GmbH, Germany).
Determination of Factor VLeiden and protrombin
G20210A mutation
To determine what, if any, mutations were har-
boured in the samples, we used the LightCycler
Factor VLeiden Mutation Detection Kit (catalog
number: 2 212 161) and the LightCycler Prothrom-
bin G20210A Mutation Detection Kit (catalog
number: 2 236 842) (Roche Diagnostics, GmbH,
Mannheim, Germany).
Principle
A fragment (222 bp for Factor V, 165 bp for Pro-
thrombin gene) of the relevant gene was amplified
using specific primers from human genomic
DNA. The amplicon was detected by fluorescence
using a pair of hybridization probes. The hybridi-
zation probes were also used to determine the
genotype, by performing a melting curve analysis,
after completion of the amplification cycles.
In this analysis, the differences between the
mutant and wild type of the related genes were
determined by assessing differences in their melt-Factor V and Prothrombin Gene Polyphmorphisms in CAD
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ing temperatures. The mutant amplicon had a
point mutation which mismatched the hybridiza-
tion probes, and so left them earlier than did the
wild type.
Measurement of lipids and lipoproteins
Apolipoprotein A (Apo A), Apolipoprotein B
(Apo B) and lipoprotein (a) (Lp a) were deter-
mined by immunoturbidometric methods. Trigly-
cerides (TG), Total cholesterol (TC) and High
Density Lipoprotein (HDL) were analyzed by
GPO/PAP enzymatic colorimetric, CHOD/PAP
enzymatic colorimetric, and direct COHD/PAP
enzymatic colorimetric methods, respectively.
Low Density Lipoprotein (LDL) content was
Table 1. Describes the Distribution of the Cases, and the Controls by Risk Factors
Variable
Patients Controls
p value
n % n %
Total (n) 181 100 106 100
Age (yrs) 58.4 ± 10.0 57.6 ± 11 0.895
Sex 0.010
Male 114 63 52 49
Female 67 37 54 51
Smoking status 0.000
Non-smokers 96 53 94 89
Current smokers 85 47 12 11
Vessel stenosis
No stenosis 106 100
One stenosis 32 18
Two stenosis 69 38
Three stenosis 93 44
Hypertension 0.000
Present 51 28 12 11
Absent 130 72 94 89
Diabetes 0.000
Present 65 36 7 6.6
Absent 116 64 99 93.4
Lipid Parameters (mg/dL)
Total cholesterol 202.5 ± 42.1 178.6 ± 25.2 0.000
HDL-Cholesterol 37.5 ± 11.1 46.2 ± 15.0 0.000
LDL-Cholesterol 119.1 ± 36.5 107.5 ± 26.6 0.000
VLDL-Cholesterol 30.1 ± 19.0 28.3 ± 14.9 0.006
Triglycerides 150.3 ± 108.0 115.9 ± 74.6 0.000
Lp (a) 27.2 ± 12.5 11.6 ± 14.3 0.000
ApoA 116.7 ± 21.3 138.5 ± 20.9 0.000
ApoB 106.4 ± 25.0 90.0 ± 16.3 0.000
n, number of samples; p, significance level; Lp (a), lipoprotein (a); ApoA, Apolipoprotein A; ApoB, Apolipoprotein B.Bahadır Ercan, et al.
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calculated from the primary measurements using
the empirical equation. All these parameters were
determined using a Cobas Integra 700 (Hitachi
Modular Systems) biochemical analyzer (Roche
Diagnostics, GmbH, Mannheim, Germany).
Statistical methods
We used percentages to express the distribution
of the mutations in the control and CAD groups.
Risk estimates were accomplished by logistic re-
gression analysis, in order to ameliorate the effects
of known risk factors such as hypertension, dia-
betes mellitus, cigarette smoking, and lipid para-
meters, on Factor VLeiden and Prothrombin
G20210A mutations. Risks are defined as the odds
ratio (OR) coupled with a confidence interval (CI).
All these statistical analyses were made using
SPSS 9.05 for Windows Version statistics program
and Minitab statistical software (Minitab release
13.0).
RESULTS
We investigated the distribution of Factor
VLeiden and Prothrombin G20210A mutation
among patients with (50% coronary artery
narrowing, and control subjects who were angio-
graphically normal (Tables 2 and 3). Seven of 106
control subjects, and 11 of 181 patients with (50
coronary artery narrowing were found to have the
Factor VLeiden mutation (Table 2). With regard to
Prothrombin G20210A, there were 7 heterozygote
genotype control subjects and 14 heterozygote
genotypes, in patients with (50% coronary artery
narrowing (Table 3). The OR for Factor VLeiden
was 1.52 (CI: 0.240 - 9.602), and for Prothrombin
G20210A mutation, the OR was 1.415 (CI: 0.287 -
6.962). Homozygotic mutations of Factor VLeiden
and Prothrombin G20210A were not detected in
either the control or the patient groups. The mean
and standard deviation of total cholesterol, HDL-
cholesterol, LDL-cholesterol, VLDL-cholesterol,
triglycerides, Lipoprotein (a), Apolipoprotein A
and Apolipoprotein B of control and patients can
be seen in Table 1.
DISCUSSION
Coronary artery disease (CAD) is a significant
cause of morbidity and mortality today. Although
CAD treatment protocols are improving, its preva-
lence has increased. Both primary and secondary
prevention measures are of vital importance.
26
Atherosclerosis is the principal cause of the car-
diovascular diseases.
27 Acute myocardial infarc-
tion (AMI) frequently results from the rupture of
an atherosclerotic plaque, followed by thrombus
formation.
28 Major risk factors for atherosclerosis
include: current smoking, hypertension, diabetes
mellitus, and dyslipidemia, including the apolipo-
protein E4 isoform.
29
The contribution of thrombogenic risk factors to
the development of AMI has been less well char-
acterized. Potential risk factors that have been
studied include: abnormalities of blood flow,
platelelet hyperactivity, reduced fibrinolysis, and
increased plasma levels of fibrinogen, factor VII,
von Willebrand factor, tissue plasminogen activa-
tor, and tissue plasminogen activator inhibitor.
30
Several genetic mutations affecting coagulation
proteins have been suggested as prothrombotic
risk factors.
15 Among these, the Prothrombin gene
and Factor VLeiden mutation have recently been
studied as potential candidates. Therefore we at-
tempted to determine whether the G20210A
Prothrombin mutation and Factor VLeiden were
associated with CAD in the population-based case
Table 2. The Distribution of the Factor VLeiden Mutation in Patients and Controls
Study group
Factor VLeiden
Wild (n) % Heterozygote (n) %
Controls 99 93.4 7 6.6
Patients 170 93.6 11 6.1
Odds ratio, 1.52 (CI: 0.240-9.602).Factor V and Prothrombin Gene Polyphmorphisms in CAD
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control study.
Prothrombin is a precursor of the serine pro-
tease thrombin, a key enzyme acting as a procoa-
gulant, via platelet activation and the generation
of fibrin and Factors Va, VIIIa and XIIIa, and
subsequently as an anticoagulant, by activating
circulating protein C. Therefore, regulation of
thrombin activity is crucial for the maintenance of
haemostatic balance.
31
In 1996, Poort et al.
9 described a variant of the
prothrombin gene that was associated with higher
prothrombin levels, and with an increased risk for
venous thrombosis. Several other studies later
confirmed these initial observations. However, the
potential role of this mutation in atherothrombotic
disease remains highly controversial.
31
Excessive thrombin generation has been de-
scribed in individuals at high risk of fatal CAD.
It seems biologically plausible that the higher
prothrombin levels related to the G20210A variant
may also confer an increased risk of CAD. To
date, however, studies attempting to answer this
question have yielded conflicting results. In some
reports, being a carrier of the mutation was asso-
ciated with an increased risk for myocardial
infarction.
16,32-34 Nevertheless, the only prospective
study published so far failed to establish any
association between the G20210A allele and MI.
35
In our study, 6.6% of control subjects harbored
the Prothrombin G20210A mutation, while 7.7% of
patients with coronary artery narrowing had this
mutation. There was found to be no difference in
the distribution of the prothrombin G20210A
mutation between patients and controls (Table 3).
Another possible prothrombotic risk factor is
the Factor VLeiden mutation. Factor VLeiden is
the most commonly known hereditary abnormality
of the clotting system, with a 3% to 5% prevalence
of heterozygote carriers. Due to mutations (Arg
506Gln or R506Q) at the cleavage site for activated
protein C (APC), clotting Factor V is inactivated
at a reduced rate. This defect leads to a reduced
anticoagulant effect of APC, with a less-than-
expected prolongation of the activated partial
thromboplastin time (APTT). The reduced anticoa-
gulant effect of the protein C/Protein S natural
inhibitor system leads to an increased tendency to
thrombosis.
22
Several studies have demonstrated an association
between resistance to activated protein C and
venous thrombosis.
36,37 Heterozygotes for this
abnormality are commonly found among unselected
patients with deep-vein thrombosis (20%), and are
even more prevalent among referred patients or
patients with familial thrombophilia (40 - 60%).
Compared to those without the mutation, hetero-
zygote carriers of the mutation carry an increased
risk of venous thrombosis.
22
Whether Factor VLeiden has any effect
whatsoever on the risk for arterial disease is
arguable, and few studies have investigated the
association. Several reports, including a controlled
study among patients with coronary stenosis, are
suggestive of an association with coronary heart
disease,
16,22,32 but in several other controlled
studies no relationship was observed.
36-39
In our study, we determined there to be no
statistical relation between the control group, and
the (50% coronary artery narrowing patients, in
terms of their Factor VLeiden mutation frequencies.
6.6% of control subjects and 6.1% of patients with
(50% coronary artery narrowing have Factor
VLeiden mutation. There was found to be no dif-
ference in the distribution of Factor VLeiden
mutation between patients and controls (Table 2).
The two mutations considered to be risk factors
for venous thrombosis are the Factor VLeiden
mutation and the Prothrombin G20210A mutation.
Table 3. The Distribution of the Prothrombin G20210A Mutation in Patients and Controls
Study group
Prothrombin G20210A mutation
Wild (n) % Heterozygote (n) %
Controls 99 93.4 7 6.6
Patients 167 92.8 14 7.7
Odds ratio, 1.415 (CI: 0.287 - 6,962).Bahadır Ercan, et al.
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In our study, we investigated whether these muta-
tions might be risk factors for coronary artery dis-
ease. Their roles in coronary artery disease were
controversial. Although heterozygote Factor
VLeiden and the Prothrombin gene mutation were
more frequent in patients with CAD than in
control subjects, there was found to be no statistical
relationship between coronary artery disease and
the Factor VLeiden and Prothrombin G20210A
mutations.
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